Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug ...

Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15%Net cash provided by operating activities of $704 millionCapital Deployment of approximately $1.2 billion Raising full ...

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug ...

Based on our robust deal pipeline, our leading position as the partner of choice in the royalty market and our efficient business model, I am confident that Royalty Pharma is well positioned to ...

The pipeline remains a focus for BioMarin ... However, the competitive landscape is evolving, with companies like Ascendis Pharma (NASDAQ:ASND) developing potential rival therapies. Analysts note that ...

BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong ...

The Danish pharmaceutical giant is putting up ... keep the alliance from spreading into areas where Ascendis’s internal pipeline already has product candidates. But Novo Nordisk has exclusive ...

In a deal worth up to $285 million initially for the lead program, Novo Nordisk will gain access to Ascendis’ TransCon ...

In August, the FDA approved Ascendis Pharma’s Yorvipath ... different groups of users across healthcare and pharma companies. The Septerna pipeline includes two preclinical negative allosteric ...

Plus: How AI can help cancer patients avoid unnecessary chemotherapies and make it easier to understand your dental X-rays.

Metsera has brought in over $500m in funding in just seven months as it looks to enter the competitive weight loss arena.